Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如乏,营养不良综合征）或既往肠手术等均影响药物的生物利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作进行系统深入的生物体内评价,解决药物透过血脑屏障和生物利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

、性别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,营养不良综合征）或既往胃肠手术等均影响的生利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点是进行系统深入的生体内评价,解决过血脑屏障和生利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

、别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,营养不良综合征）或既往胃肠手术等均影响的生利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点是进行系统深入的生体内评价,解透过血脑屏障和生利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表、、疾病（如胃酸缺乏,营养不良综合征）或既往胃肠手术等均影响药物的生物利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点是进行系的生物体内评价,解决药物透过血脑屏障和生物利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,营养不良综合征）或既往胃肠手术等均影响物的生物利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点是进行系统深入的生物体内评价,解决物透过血脑屏障和生物利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,营养不良综合征）胃肠手术等均影响药的生度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点是进行系统深入的生体内评价,解决药透过血脑屏障和生度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,营养不良综合征）或既往胃肠手术等均影响药物的物。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点是进行系统深入的物体内评价,解决药物透过血脑屏物等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（缺乏,营养不良综合征）或既往肠手术等均影响药物的生物利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重行系统深入的生物体内评价,解决药物透过血脑屏障和生物利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如酸缺乏,营养不良综合征）或既手术等均影响药利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后工作重点是进行系统深入体内评价,解决药透过血脑屏障和利用度等问题。